Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

venetoclax 190Cyclophosphamide 123Azacitidine 112Cytarabine 108fludarabine 91Specimen Handling 74Biopsy 53Daunorubicin 42Methotrexate 41Dexamethasone 38Rituximab 34blinatumomab 32Vincristine 32Decitabine 31fludarabine phosphate 30Injections 28Granulocyte Colony-Stimulating Factor 28Whole-Body Irradiation 26Magnetic Resonance Spectroscopy 26obinutuzumab 25Idarubicin 25acalabrutinib 23Prednisone 23Mycophenolic Acid 23Melphalan 21Busulfan 21gilteritinib 19Mercaptopurine 19Doxorubicin 19ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cytochrome P-450 CYP3A × Other hematologic neoplasm × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡